Cargando…
Late Cardiotoxicity in MS Patients Treated with Mitoxantrone
CONTEXT: Mitoxantrone (MTX) is an antracyclin drug that is used for treatment of patients with chronic refractory multiple sclerosis (MS). Congestive heart failure (CHF) is a rare complication of this drug that may occur early, during therapy, or late, months or years after termination of therapy. A...
Autores principales: | Najafian, Jamshid, Nasri, Ali, Etemadifar, Masoud, Salehzadeh, Fardin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941302/ https://www.ncbi.nlm.nih.gov/pubmed/31921403 http://dx.doi.org/10.4103/ijpvm.IJPVM_477_17 |
Ejemplares similares
-
Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study
por: Tabrizi, Nasim, et al.
Publicado: (2012) -
Cardiotoxicity of Mitoxantrone Treatment in a German Cohort of 639 Multiple Sclerosis Patients
por: Fleischer, Vinzenz, et al.
Publicado: (2014) -
Inflammation as a Possible Trigger for Mitoxantrone-Induced Cardiotoxicity: An In Vivo Study in Adult and Infant Mice
por: Reis-Mendes, Ana, et al.
Publicado: (2021) -
Epicardial fat thickness and severity of coronary heart disease in patients with diabetes mellitus type II
por: Nasri, Ali, et al.
Publicado: (2018) -
Assessment of late cardiotoxic effects in patients treated for cancer in childhood
por: Kincl, Vladimír, et al.
Publicado: (2022)